Results 211 to 220 of about 32,102 (275)
Prophylactic use of a combination of palonosetron hydrochloride and dexamethasone to prevent transcatheter arterial chemoembolization-induced nausea and vomiting among patients with hepatocellular carcinoma. [PDF]
Front Med (Lausanne)Zhang WM +6 more
europepmc +1 more source
Prior Authorization, Quantity Limits, and Step Therapy for Patient-Administered Antiemetics.
JAMA Netw OpenVu K +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Anaesthesiology, 2002
Numerous studies about postoperative nausea and vomiting management are available and meta-analyses have helped to define the appropriate doses of the effective drugs. Almost all recent papers include some economical considerations. In order to rationalize the therapeutic protocols, strategies including systematic prophylaxis, treatment of established ...
Pierre, Diemunsch, Anne-Marie, Diemunsch
openaire +2 more sources
Numerous studies about postoperative nausea and vomiting management are available and meta-analyses have helped to define the appropriate doses of the effective drugs. Almost all recent papers include some economical considerations. In order to rationalize the therapeutic protocols, strategies including systematic prophylaxis, treatment of established ...
Pierre, Diemunsch, Anne-Marie, Diemunsch
openaire +2 more sources
Current Opinion in Oncology, 1997
In the past few years a combination of a 5-HT3 receptor antagonist plus dexamethasone has been shown to be the most efficacious antiemetic prophylaxis of acute emesis induced by cisplatin and moderately emetogenic chemotherapy. In the prevention of cisplatin-induced delayed emesis oral metoclopramide or ondansetron, both combined with dexamethasone ...
F, Roila, A, Del Favero
openaire +2 more sources
In the past few years a combination of a 5-HT3 receptor antagonist plus dexamethasone has been shown to be the most efficacious antiemetic prophylaxis of acute emesis induced by cisplatin and moderately emetogenic chemotherapy. In the prevention of cisplatin-induced delayed emesis oral metoclopramide or ondansetron, both combined with dexamethasone ...
F, Roila, A, Del Favero
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2002
The emetogenic potential of cancer chemotherapeutic agents varies according to the agent employed. Among the highly emetogenic agents, cisplatin has been the most studied. As for emesis induced by cisplatin, an optimal antiemetic schedule is effective in 70-90% of cases of acute emesis, in 60% of cases of delayed emesis, whereas acute emesis induced by
L. Licitra, S. Spinazzé, F. Roila
openaire +3 more sources
The emetogenic potential of cancer chemotherapeutic agents varies according to the agent employed. Among the highly emetogenic agents, cisplatin has been the most studied. As for emesis induced by cisplatin, an optimal antiemetic schedule is effective in 70-90% of cases of acute emesis, in 60% of cases of delayed emesis, whereas acute emesis induced by
L. Licitra, S. Spinazzé, F. Roila
openaire +3 more sources
Metoclopramide as an Antiemetic
Annals of Internal Medicine, 1981Excerpt To the editor: We read with interest the review by Seigel and Longo (1) on the control of chemotherapy-induced emesis.
S B, Strum, J E, McDermed
openaire +2 more sources
Gastroenterology Clinics of North America, 1992
This article explores recent knowledge on the physiology and neuropharmacology of the emetic process. It seeks to outline the indications for specific antiemetic drugs and where their actions are targeted. Much of the information for the role of antiemetic drugs has come from experience with antiemetics in patients receiving cytotoxic chemotherapy. The
openaire +2 more sources
This article explores recent knowledge on the physiology and neuropharmacology of the emetic process. It seeks to outline the indications for specific antiemetic drugs and where their actions are targeted. Much of the information for the role of antiemetic drugs has come from experience with antiemetics in patients receiving cytotoxic chemotherapy. The
openaire +2 more sources
Current Opinion in Oncology, 1992
Despite major progress in the treatment of chemotherapy-induced emesis, nearly one third of patients undergoing cisplatin-based regimens still experience emesis within the first 24 hours of chemotherapy. An adequate treatment of delayed and anticipatory emesis remains to be determined.
openaire +3 more sources
Despite major progress in the treatment of chemotherapy-induced emesis, nearly one third of patients undergoing cisplatin-based regimens still experience emesis within the first 24 hours of chemotherapy. An adequate treatment of delayed and anticipatory emesis remains to be determined.
openaire +3 more sources
Journal of Palliative Care, 1993
The choice of antiemetic should not be arbitrary, but should be based on knowledge of the different pathways of the various stimuli that lead to nausea and vomiting and the neuroreceptors involved. The steps to be taken in choosing an appropriate antiemetic are described.
openaire +2 more sources
The choice of antiemetic should not be arbitrary, but should be based on knowledge of the different pathways of the various stimuli that lead to nausea and vomiting and the neuroreceptors involved. The steps to be taken in choosing an appropriate antiemetic are described.
openaire +2 more sources